Stock Analysis on Net
Stock Analysis on Net

Moderna Inc. (NASDAQ:MRNA)

Common-Size Income Statement

Moderna Inc., common-size consolidated income statement

Microsoft Excel
12 months ended: Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019
Net product sales 100.00 100.00 100.00 100.00 0.00
Cost of sales -70.35 -29.38 -14.81 -3.97 0.00
Gross profit 29.65% 70.62% 85.19% 96.03% —
Other revenue 2.65 4.49 4.50 301.95 0.00
Research and development -72.63 -17.87 -11.26 -685.61 0.00
Selling, general and administrative -23.22 -6.14 -3.21 -94.19 0.00
Income (loss) from operations -63.54% 51.10% 75.22% -381.82% —
Interest income 6.31 1.08 0.10 12.37 0.00
Gain (loss) on investments -1.08 -0.11 0.01 0.65 0.00
Interest expense -0.57 -0.16 -0.10 -4.95 0.00
Other income (expense), net -0.21 0.02 -0.07 1.25 0.00
Other expense, net -1.86% -0.24% -0.16% -3.04% —
Income (loss) before income taxes -59.09% 51.94% 75.16% -372.49% —
(Provision for) benefit from income taxes -11.57 -6.58 -6.13 -1.28 0.00
Net income (loss) -70.66% 45.36% 69.04% -373.77% —

Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).

Income statement item Description The company
Income (loss) from operations The net result for the period of deducting operating expenses from operating revenues. Moderna Inc. income (loss) from operations as a percentage of net product sales decreased from 2021 to 2022 and from 2022 to 2023.
Income (loss) before income taxes Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. Moderna Inc. income (loss) before income taxes as a percentage of net product sales decreased from 2021 to 2022 and from 2022 to 2023.
Net income (loss) The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Moderna Inc. net income (loss) as a percentage of net product sales decreased from 2021 to 2022 and from 2022 to 2023.